Racura Oncology: Lung Cancer trial targets resistance

Racura Oncology is advancing clinical trials for cancer treatments, including a lung cancer trial (HARNESS-1) combining their drug with osimertinib to address resistance, and preparing for a Phase 3 trial in acute myeloid leukaemia. Early data from the lung cancer trial is…

Listen